Problems viewing this newsletter? View it in your browser >

October 15, 2012

Dear Advocate,

This is an exciting moment in the response to AIDS. Leading scientists, policy makers, advocates, and others believe we can begin to end the pandemic. But we will not realize this potential automatically. It will take choices: about increasing investment, using funds strategically, learning as we go, and holding ourselves accountable.

We are pleased to announce the release of this quarter’s issue of Px Wire (Volume 5, Issue 4), AVAC’s quarterly update on HIV prevention research.

Click here to download the current issue.

Px Wire features an advocates’ guide to the “sieve analysis” from the RV144 vaccine trial. This latest follow-up investigation provided further detail about the partial protection associated with the vaccine strategy.

We also update readers with the latest on trials of ARV-containing vaginal rings—the next frontier in microbicide development.

In the centerspread, you’ll find key graphics and captions from Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research and Development, issued by the HIV Vaccines and Microbicides Resource Tracking Working Group. We hope this information will help you tell the story of investment in HIV prevention research and development funding in 2011. More complete data are available

Additional resources including the Px Wire archive, information about subscribing, reprint requests and bulk orders can be found at

As always, comments are most welcome at



October 7, 2013: AIDS Vaccine 2013,
in Barcelona, Spain
The annual AIDS Vaccine conference is the largest and most diverse international meeting of researchers, advocates, clinicians, private sector partners and public health experts working collaboratively to advance HIV vaccine science.


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423